VCNX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 geg. 2024 @ 23:00):

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs...

Stats
Šios dienos apimtis	10 063.00
Vidutinė apimtis	14 287.00
Rinkos kapitalizacija	8.55M
EPS	$0 ( 2024-04-02 )
Kita pelno data	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.140
ATR14	$0.179 (2.98%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Friedberg Albert	Buy	282	Common Stock
2024-03-28	Zauderer Maurice	Buy	38 610	Common Stock
2024-03-28	Zauderer Maurice	Buy	38 610	Warrant (Right to Buy)
2024-03-28	Friedberg Albert	Buy	102 960	Common Stock
2024-03-28	Friedberg Albert	Buy	102 960	Warrant (Right to Buy)

INSIDER POWER
99.87
Last 100 transactions
Buy: 40 266 892 \| Sell: 9 809 782

Vaccinex Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Vaccinex Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$570 000
Bruto pelnas:	$451 000 (79.12 %)
EPS:	$-43.68

FY	2023
Pajamos:	$570 000
Bruto pelnas:	$451 000 (79.12 %)
EPS:	$-43.68

FY	2022
Pajamos:	$100 000
Bruto pelnas:	$-107 000 (-107.00 %)
EPS:	$-97.59

FY	2021
Pajamos:	$900 000
Bruto pelnas:	$900 000 (100.00 %)
EPS:	$-1.191

Financial Reports:

No articles found.

Vaccinex Inc

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.